Idexx Laboratories (IDXX) net income: $1.1B
Idexx Laboratories reported a net income of $1.1B for the year ended Dec 31, 2025, up 19.3% from $888M a year earlier.
From Idexx Laboratories's filings with the SEC · Read the filing · IDXX stock page
Idexx Laboratories net income by year
#361 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | $1.1B | +19% |
| Dec 31, 2024 | $888M | +5% |
| Dec 31, 2023 | $845M | +24% |
| Dec 31, 2022 | $679M | -9% |
| Dec 31, 2021 | $745M | – |
Net income of similar companies
Companies in the same industry as Idexx Laboratories, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| TEVA Pharmaceutical Industries | $1.4B | Dec 31, 2025 |
| United Therapeutics | $1.3B | Dec 31, 2025 |
| Biogen | $1.3B | Dec 31, 2025 |
| Idexx Laboratories | $1.1B | Dec 31, 2025 |
| Exelixis | $783M | Jan 2, 2026 |
| Royalty Pharma | $771M | Dec 31, 2025 |
| PTC Therapeutics | $683M | Dec 31, 2025 |
Questions and answers
What is Idexx Laboratories's net income?
Idexx Laboratories reported a net income of $1.1B for the year ended Dec 31, 2025, up 19.3% from $888M a year earlier.
Numbers as reported in Idexx Laboratories's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology